GOOGL
MRK
Merck just bought a seat at the AI table
Merck said it’s partnering with Google Cloud to turn itself into an AI-enabled enterprise, using Gemini Enterprise and a team of Google Cloud engineers to help wire up the company’s research, manufacturing, commercial, and corporate operations.
The headline number here is the one that makes CFOs clutch their calculators: the deal is valued at up to $1 billion over multiple years. That’s not pocket change, even for a pharma giant. It signals Merck isn’t just dabbling in generative AI for a press release cameo — it’s trying to make AI part of the company’s actual operating system.
Why investors should care
If this works, the payoff could be pretty boring in the best way possible: faster drug discovery, smoother manufacturing, better workflow automation, and maybe fewer human bottlenecks in all the places where big companies usually move like a grocery cart with one bad wheel.
But there’s a catch. Big transformation projects can also turn into expensive IT therapy sessions if the tech never translates into real productivity gains. So the market will probably want proof that this partnership does more than generate buzzwords and nice conference-stage lighting.
The bigger picture
For Merck, this fits the broader “pharma company meets software company” trend. Drugmakers are increasingly leaning on cloud and AI tools to squeeze more speed and efficiency out of massive, regulated operations.
Big picture: if Merck can make agentic AI actually help move molecules, factories, and paperwork faster, that billion-dollar tag could start looking like an investment instead of an indulgence.